Another double-blind, placebo-controlled, randomized, 6-week trial also examined the efficacy of sustained release bupropion in adults with ADHD in the short-term. The inclusion criteria for patients in this study was that they had to be at least 18 years of age, have a score of at least 15 on the Wender-Reimherr Adult Attention Deficit Disorder Scale (WRAADDS), and meet the criteria for ADHD under both the DSM-IV as well as the Utah criteria. Patients were excluded if they had a bipolar, depressive mood, schizophrenic, borderline personality, or antisocial personality disorder under the Utah criteria. Other exclusion criteria included any history of stimulant drug abuse, eating disorders, seizure disorders, history of head trauma, prior treatment with bupropion, and being at risk for suicide. This study used the Clinical Global Impressions-Improvement (CGI-I) and WRAADDS to determine whether bupropion had an effect in treating ADHD. A reduction in the WRAADDS of at least 50% or a CGI-I score of 1-2 were considered to be responding to the treatment. Of the 59 patients (n=59; 43 males, 16 females) enrolled in this study, 60% were assigned to the bupropion SR group and 40% were assigned to the placebo group in the hope that they would be able to enroll the patients in the bupropion group in a longer-term study. When it came to reporting ADHD symptoms, self-reported information from the patient and information provided by a close family member were used. The 6-week double blind part of the study was proceed by a 1-week baseline period which involved a single-blind placebo administration.1 In terms of results, only 47 out of the original 59 patients completed the full 6 weeks of the study (29 patients in the bupropion group, 18 in the placebo). No significant adverse events were reported in either the placebo or bupropion groups. When analyzing the CGI-I scores, the authors concluded that there was no significant difference between the bupropion and placebo groups (p =0.15). With the WRAADDS scores, a fisher’s exact test showed a statistically significant difference in a 50% improvement of scores with bupropion over placebo (p <0.05), but only if they were looking at the period between the initial screening portion and the end of the 6-week study. From the end of the 1-week single-blind period to the end of the 6-week double-blind period, there was no statistical significant difference in WRAADDS score improvement between placebo and bupropion (p = 0.15). The authors concluded that the way they divided the patients (60:40, bupropion:placebo) may have affected their results.